Patients from 22+ countriesPlan your visit →
lutetium-therapy
Patient Journey · 20 Aug 2026

Maintaining Muscle Mass During Lu-177 PSMA Therapy

Men with mCRPC on Lu-177 PSMA therapy face muscle loss from three directions at once - the cancer itself, testosterone suppression from ADT, and reduced activity between cycles. Here is what nutrition and exercise evidence says you can do about it.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 20 Aug 2026
Maintaining Muscle Mass During Lu-177 PSMA Therapy

Maintaining Muscle Mass During Lu-177 PSMA Therapy

This article is on the PSMA track and is written for men with metastatic castration-resistant prostate cancer (mCRPC) who are receiving or weighing up lutetium Lu-177 vipivotide tetraxetan - also sold under the brand name Pluvicto. If you have noticed weight loss, weakness, or shrinking muscles during treatment, you are not alone.

Muscle loss is one of the most common challenges facing men with advanced prostate cancer during any line of therapy. The good news is that targeted changes to how you eat and how you move may help slow this process, protect your strength, and support your tolerance to treatment across cycles.

Quick answer: During Lu-177 PSMA therapy for mCRPC, muscle loss comes from three overlapping forces: the cancer triggers inflammatory pathways that break down muscle, ADT removes the testosterone your muscles need to stay strong, and fatigue reduces physical activity. Resistance exercise and higher protein intake are the two most evidence-backed strategies to slow this loss.

What Is Cancer Cachexia?

Cachexia (pronounced ka-KEX-ee-ah) is the medical term for the combination of muscle wasting and weight loss that comes with serious illness. It is not simply a lack of appetite. The cancer itself drives this biological process.

Prostate cancer cells - particularly in advanced or castration-resistant disease - release inflammatory signals into your bloodstream. These signals change how your body handles protein. Your body activates protein-degradation pathways that break down muscle faster than it can be rebuilt. Research published in PubMed Central on cancer cachexia mechanisms identifies the ubiquitin-proteasome system and autophagy as the key intracellular pathways involved - these are molecular systems that dismantle muscle proteins when the cancer is present.

What this means in practice is that eating more calories alone will not reverse cachexia. You need a strategy that directly addresses what the disease is doing at a cellular level. That means combining protein-targeted nutrition with physical stimulus through exercise.

Why Muscle Loss Is Compounded During Lu-177 PSMA Treatment

Men receiving lutetium Lu-177 vipivotide tetraxetan for mCRPC are almost always also on androgen deprivation therapy (ADT). ADT reduces testosterone to very low levels. Testosterone plays a central role in building and maintaining skeletal muscle - so when it falls, muscle mass tends to follow.

A review published in Frontiers in Oncology confirms that ADT leads to increases in fat mass alongside decreases in lean muscle mass, with a meaningful risk of sarcopenia - a clinical term for the loss of muscle mass and function that goes beyond normal ageing. A separate study tracking prostate cancer patients on ADT found that sarcopenia became significantly more prevalent as treatment continued, and that this muscle loss was linked to worse health outcomes unrelated to the cancer itself.

On top of ADT, the treatment cycle itself can reduce how much you move. Lutetium Lu-177 vipivotide tetraxetan infusions are typically given every six weeks. In the days after each infusion, nausea, fatigue, and radiation-precaution requirements can reduce your physical activity. Less movement means less stimulus for your muscles to maintain themselves.

Three forces - disease biology, ADT-driven hormone suppression, and reduced activity - can work together against your muscle tissue at the same time. Naming all three helps you target each one deliberately rather than hoping a single fix will cover everything.

Why Muscle Mass Has Real Clinical Stakes

Muscle mass during cancer treatment carries concrete clinical consequences:

  • Treatment tolerance: Patients with more lean body mass generally tolerate systemic therapies better. Your body's ability to process and recover from each Lu-177 infusion depends in part on your overall physical reserve.
  • Fatigue: Muscle loss makes fatigue worse. Weaker muscles require more effort for everyday tasks - standing, walking, getting dressed - which drains energy faster.
  • Bone protection: Many men with mCRPC have bone metastases. Strong muscles around affected bones help absorb mechanical stress during movement and may reduce the risk of falls and fractures during daily activities.
  • Future eligibility for therapy: Your functional status is part of how your team assesses whether you can continue treatment or move to an additional line. Protecting muscle now may support more options later. For context on what your team looks at after treatment ends, see our article on what to monitor after your Lu-177 PSMA cycles and how next steps are decided.

What Does the Evidence Show About Exercise?

Resistance training - using weights, resistance bands, or your own body weight to load your muscles against a force - has the most consistent published evidence for fighting muscle loss during prostate cancer treatment. Multiple studies show that resistance training preserves lean body mass and muscle strength during ADT.

A peer-reviewed clinical study on resistance training in prostate cancer found that resistance exercise can effectively counteract ADT-induced loss of lean body mass and muscle strength, and is safe during prostate cancer treatment. The authors recommended it as part of standard clinical care. Exercise oncology guidance suggests resistance training that activates all major muscle groups at least twice a week for individuals living with any stage of prostate cancer.

Aerobic exercise - walking, gentle cycling, swimming - adds additional benefit. A systematic review on nutrition therapy and exercise in men with prostate cancer found that structured exercise, especially when combined with dietary support, helps manage cancer-related fatigue better than either approach alone.

Exercise gains in muscle and strength tend to decline when supervised training stops - meaning consistency matters more than intensity. Even modest, regular effort over many weeks is likely to produce more benefit than occasional bursts of high activity.

Exercise Safety During a Lu-177 PSMA Cycle

In the first few days after an infusion, your body is clearing radiotracer through urine and saliva. Your nuclear medicine team will give you specific radiation-safety precautions for that window - including guidance on physical contact and hygiene. High-intensity gym sessions and close-contact environments are best deferred until those precautions no longer apply.

Light to moderate activity - walking, home-based resistance exercises with bands or body weight, gentle stretching - is generally reasonable even during that early window, but confirm this with your nuclear medicine or oncology team first before acting on it.

If you have bone metastases, share that information with any physiotherapist or exercise professional before starting a programme. Certain loading patterns may carry fracture risk in affected bones. A physiotherapist with oncology experience can build a plan that protects high-risk areas while still challenging your muscles elsewhere. Ask your treatment centre whether a cancer rehabilitation or physiotherapy referral is available.

What Should You Eat to Protect Your Muscles?

Your muscles are made mostly of protein. During cancer treatment, your body's demand for protein rises because the inflammatory environment accelerates protein breakdown. General adult guidelines for protein intake are typically set well below what oncology nutrition research suggests cancer patients may need.

The systematic review cited above found that muscle mass maintenance during cancer treatment was associated with protein intake above approximately 1.4 grams per kilogram of body weight per day, while patients consuming below 1.2 grams per kilogram lost muscle. For a man weighing 75 kg (165 lb), the higher figure means roughly 105 grams of protein daily. Good sources include eggs, fish, chicken, legumes, dairy products, soy-based foods like tofu and edamame, and protein supplements when appetite is low.

A few practical nutrition principles to consider alongside your protein target:

  • Spread protein across the day: Consuming protein at every meal and snack - rather than most of it at dinner - may support more consistent muscle protein synthesis. Aim for a protein source at breakfast, lunch, and your evening meal.
  • Prioritise anti-inflammatory foods: Oily fish, colorful vegetables, olive oil, nuts, and whole grains contain nutrients that may help reduce some of the inflammatory signalling driving cachexia. A varied, plant-rich diet is what most oncology dietitians tend to support alongside adequate protein.
  • Plan for low-appetite days: Nausea and taste changes are common in the days after an infusion. Prepare easy, high-protein options in advance - boiled eggs, yogurt, hummus, cheese, fortified shakes - so you have something accessible when your appetite is limited. Small, frequent portions tend to be better tolerated than large meals during that period.
  • Stay hydrated: Adequate fluid intake supports your kidneys in clearing the radiotracer after each cycle. It also supports physical performance and may reduce fatigue between infusions.

If you are losing weight faster than expected, or if eating has become genuinely difficult, ask your oncology team for a referral to a registered oncology dietitian. This is an evidence-based clinical resource, not a luxury. High-protein supplements can help bridge a gap when food intake is limited, but solid food remains the first choice when possible.

What About Supplements Like Protein Powder or Creatine?

Creatine monohydrate is among the most studied supplements for muscle preservation in general populations, and researchers are exploring whether it benefits cancer patients in combination with resistance training - including in ongoing clinical trials. Evidence-based guidance for cancer patients specifically is still emerging, so it is too soon to make a firm recommendation either way.

Protein powders - whey, casein, plant-based blends - may help close a gap between what you are eating and your daily protein target, but the current evidence base supports a food-first approach. Supplements are a practical fallback when solid food intake is genuinely limited, not a replacement for dietary protein from whole foods.

Before adding any supplement to your routine - including seemingly mild ones - discuss it with your oncologist or pharmacist. Some products can affect kidney function, which your team is already monitoring carefully during Lu-177 PSMA therapy. Others may interact with medications used in mCRPC management in ways that are not immediately obvious.

What If You Are Already Frail or Have Lost Significant Weight?

Significant muscle loss or frailty does not automatically disqualify you from Lu-177 PSMA therapy. Your team assesses eligibility case by case, and individual circumstances matter. Our article on Lu-177 PSMA therapy for frail mCRPC patients who cannot tolerate chemotherapy covers what that assessment tends to look like in practice and what the published evidence shows for this group.

If you feel that declining muscle mass or functional status may be affecting how your team views your ability to continue treatment - or if you want an independent view on whether Lu-177 PSMA remains appropriate alongside supportive nutrition and exercise interventions - you can request a Lu-177 eligibility review through Art of Healing Cancer. Their nuclear medicine team can assess your current status in the context of your scan findings, treatment history, and functional level, and advise whether additional supportive measures should be part of your plan.

A Short Checklist for Your Next Oncology Appointment

Bring these questions to your next appointment:

  • Can you refer me to a physiotherapist with oncology experience who can design an exercise plan around my bone metastases and treatment cycle schedule?
  • Should I see a registered oncology dietitian, given the weight I have lost recently?
  • Which days after my next infusion can I safely resume or begin exercise?
  • Is any medication I am currently taking affecting my appetite or muscle metabolism in ways I should know about?
  • Should my protein and calorie intake be formally tracked between cycles as part of my monitoring plan?

If you are travelling to India for treatment cycles, ask ahead of time whether the centre you are using has a nutrition or rehabilitation service available during your stay. Arranging this before your first cycle is far easier than trying to organise it mid-treatment. For a broader guide to what to plan in advance, see our article on planning your India trip for Lu-177 PSMA therapy.

When to Talk to Your Doctor

Contact your oncology team promptly if you notice any of the following between cycles:

  • Unintentional weight loss of more than 2-3 kg in the weeks between infusions
  • A noticeable drop in how far or how long you can walk compared with the previous cycle
  • Severe nausea or appetite loss that prevents eating for more than two consecutive days
  • New or worsening weakness in your legs or arms
  • A fall, or a near-fall, during a routine daily activity

These signals do not necessarily mean your treatment is failing. They are clinical indicators that your supportive care plan may need adjusting - and the earlier your team knows, the more options they have.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Can I exercise during Lu-177 PSMA therapy?

In most cases, yes - but the timing and type of exercise need to match where you are in your cycle. In the first few days after an infusion, radiation precautions apply and close-contact gym environments are best avoided. Home-based activities like walking and light resistance exercises are often still possible during that window. Always confirm with your nuclear medicine team before starting or changing an exercise routine, and work with a physiotherapist who has oncology experience, particularly if you have bone metastases.

How much protein should I eat to protect my muscles during treatment?

Oncology nutrition research suggests that cancer patients may need protein well above the standard adult recommendation. Evidence reviewed in a published systematic review found muscle maintenance was associated with protein intake above approximately 1.4 grams per kilogram of body weight per day, while intake below 1.2 grams per kilogram was linked to muscle loss. For a man weighing 75 kg, the higher target means roughly 105 grams of protein daily. A registered oncology dietitian can give you a personalised figure based on your weight, kidney function, and treatment status.

Is muscle loss during Lu-177 PSMA therapy a sign the treatment is not working?

Not necessarily. Muscle loss in mCRPC can happen because of the cancer itself, the androgen deprivation therapy you are likely on, reduced physical activity, or a combination of all three - not specifically because lutetium Lu-177 vipivotide tetraxetan is failing to work. Your team will track PSA levels, imaging findings, and other markers to assess treatment response separately. If you are concerned about muscle loss, raise it directly so your team can assess and put nutritional or exercise support in place.

Should I take creatine or protein supplements during treatment?

Creatine and protein supplements are being studied in cancer patients and may offer some benefit in combination with resistance training, but evidence specific to men on Lu-177 PSMA therapy is still emerging. The general guidance is to try to meet protein targets through food first, and use supplements to fill a genuine gap rather than as a primary strategy. Before starting any supplement - even ones sold over the counter - discuss it with your oncologist or pharmacist, as some products can affect kidney function or interact with medications used in mCRPC management.

What is the difference between cancer cachexia and simply not eating enough?

Cachexia is a disease-driven biological process, not just poor appetite or low food intake. The cancer releases inflammatory signals that change how your body metabolises protein, causing muscle to break down faster than it can be rebuilt - even when calorie intake looks adequate. This is why simply eating more food rarely reverses cachexia on its own. Managing it requires addressing the underlying cancer through treatment, increasing protein intake, using resistance exercise to stimulate muscle repair, and in some cases medication prescribed specifically for cachexia management.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.